US · VERO
Venus Concept Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Toronto, ON M2J 4Y8
- Website
- venusconcept.com
Price · as of 2024-12-31
—
Market cap 3.92M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $116.02 | — |
| Intrinsic Value(DCF) | $1.21 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $412.12 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $0.00 | $183.57 | |||
| 2017 | $14,404.50 | $5,767.12 | $116.47 | $0.00 | $0.00 |
| 2018 | $1,905.75 | $860.50 | $0.00 | $0.00 | $0.00 |
| 2019 | $965.25 | $475.52 | $2,390,661.77 | $0.00 | $0.00 |
| 2020 | $442.20 | $238.24 | $92.92 | $0.00 | $678.06 |
| 2021 | $231.00 | $255.67 | $904.24 | $0.00 | $0.00 |
| 2022 | $34.98 | $15.12 | $0.00 | $0.00 | $0.00 |
| 2023 | $9.24 | $131.30 | $0.00 | $0.00 | $96.25 |
| 2024 | $3.03 | $116.02 | $0.00 | $0.00 | $412.12 |
AI valuation
Our deep-learning model estimates Venus Concept Inc.'s (VERO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $116.02
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.21
— upside
Graham-Dodd
—
— upside
Graham Formula
$412.12
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VERO | Venus Concept Inc. | $2.11 | 3.92M | +5,399% | -43% | — | +19,432% | -0.05 | 0.91 | 0.03 | -1.14 | -0.01 | -0.83 | 68.34% | -41.93% | -72.49% | 806.37% | -52.93% | -58.05% | 18.16 | -3.55 | 1.60 | 0.78 | -1.08 | 86901.00% | -1509.00% | -1376.00% | -520.15% | -0.37 | -22.07% | 0.00% | 0.00% | 1652.41% | -1.50 | -3.66 | 0.63 | -6.37 |
| BBLG | Bone Biologics Corporatio… | $2.01 | 3.61M | — | — | — | — | -1.86 | 2.19 | — | 40.32 | — | 2.19 | 0.00% | — | — | -128.71% | -22020.98% | -108.23% | 0.00 | — | 10.22 | 8.80 | -31.03 | -8580.00% | — | -5683.00% | -53.95% | -10.92 | -21530.04% | 42.02% | -78.10% | 45.92% | -1.02 | -1.05 | — | -21.20 |
| BGMS | Bio Green Med Solution, I… | $1.65 | 3.69M | +1,306,220% | +2,232,759% | — | +2,368,039% | -0.07 | -0.38 | 19.24 | 0.19 | — | -0.38 | 100.00% | -27916.28% | -26074.42% | 1431.01% | 278.96% | -173.84% | 0.00 | — | 0.59 | 0.54 | 0.26 | -9219.00% | -8976.00% | -5043.00% | -965.78% | -1.27 | 198.63% | 0.00% | 0.00% | 0.00% | 0.19 | 0.29 | -53.71 | -160.64 |
| BNBX | Stader BNB | $3.46 | 4.47M | — | — | — | — | -0.10 | 0.67 | 0.73 | -0.01 | — | 0.67 | 39.26% | -750.92% | -709.46% | — | — | — | 0.08 | — | 0.91 | 0.77 | 0.09 | — | — | — | -826.25% | -5.08 | — | 0.00% | 0.00% | 0.00% | 0.00 | -0.01 | 0.04 | -130.76 |
| DHAI | DIH Holding US, Inc. | $1.82 | 3.81M | +1,508% | +20% | — | — | -903.76 | -211.15 | 124.73 | -1104.70 | — | -211.15 | 51.24% | -7.74% | -13.80% | 24.90% | 20.72% | -27.77% | -0.32 | -15.34 | 0.49 | 0.12 | -1.41 | -2412.00% | -250.00% | -19379.00% | -0.06% | -0.10 | 19.94% | 0.00% | 0.00% | 0.03% | -1614.12 | -1677.58 | 124.89 | 72.12 |
| GRI | GRI Bio, Inc. | $1.68 | 4.23M | +10,214% | — | — | — | -0.02 | 0.04 | — | 0.66 | — | 0.04 | 0.00% | — | — | -238.17% | 791.34% | -166.00% | 0.01 | — | 3.25 | 3.11 | 0.68 | -9212.00% | -10000.00% | 1833.00% | -4086.53% | -3.85 | 673.21% | 0.00% | 0.00% | 1303.49% | 0.66 | 0.78 | — | -12.03 |
| HSCS | HeartSciences Inc. | $2.90 | 6.52M | +667% | -43% | — | +20,854% | -0.45 | 19.02 | 897.28 | -0.71 | — | -2.77 | -2884.71% | -192013.13% | -201499.52% | -233.04% | -360.16% | -127.72% | 14.55 | -16.69 | 0.59 | 0.30 | -0.23 | -5016.00% | -7661.00% | 2014.00% | -190.70% | -2.00 | -320.95% | 0.00% | 0.00% | 0.00% | -0.69 | -0.78 | 1331.10 | -31.62 |
| MOVE | Movano Inc. | $5.30 | 3.79M | — | — | — | — | -90.32 | 291.38 | 2115.60 | -88.77 | — | 291.38 | -196.84% | -2391.12% | -2342.25% | -439.23% | 1722.15% | -228.79% | 0.03 | — | 3.02 | 2.31 | 0.32 | -3810.00% | — | -1410.00% | -1.05% | -6.54 | 1602.63% | 0.00% | 0.00% | 0.08% | -88.16 | -94.73 | 2107.98 | 299.75 |
| NAOV | NanoVibronix, Inc. | $4.84 | 3.86M | +29,176% | +225% | — | — | -2.87 | 16.95 | 4.15 | -2.71 | — | 16.95 | 58.95% | -140.03% | -144.84% | -160.56% | -1021.97% | -71.92% | 0.19 | -26.53 | 1.22 | 0.37 | 0.17 | -3524.00% | 1205.00% | -3009.00% | -23.70% | -0.92 | -718.69% | 0.00% | 0.00% | 0.00% | -2.79 | -3.97 | 3.91 | -27.16 |
| NDRA | ENDRA Life Sciences Inc. | $5.21 | 3.92M | — | — | — | — | -0.34 | 1.54 | — | -0.12 | -0.46 | 1.54 | 0.00% | — | — | -280.02% | -690.14% | -205.38% | 0.23 | — | 5.67 | 5.34 | 0.25 | 7402.00% | — | -2260.00% | -188.25% | -12.23 | -473.18% | 0.13% | 0.00% | 5.35% | -0.12 | -0.17 | — | -38.53 |
About Venus Concept Inc.
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
- CEO
- Rajiv Kanishka Liyanaarchchie De Silva
- Employees
- 292
- Beta
- -0.11
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.21 ÷ —) − 1 = — (DCF, example).